AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04707560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS fine needle biopsy with heparin wet suction
Description: EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion.
Study NCT03758105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS associated with usual care
Description: A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks.
Study NCT03758105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Medication and psychotherapy as prescribed in usual care
Study NCT04151966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for markers of myocardial injury
Study NCT04727255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaged and Resilient intervention
Description: Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology.
Study NCT01892878 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: VerteLoc
Description: Single Arm
Study NCT03462992 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MonoMark
Description: MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
Study NCT01329666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
Study NCT01329666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks.
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 \& 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days
Study NCT00494026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
Study NCT00494026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
Study NCT04106570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fatiguability of the knee extensors
Description: fatiguability of the knee extensors (in N.m) measured with a dynamometer.
Study NCT02354547 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
Study NCT02354547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
Study NCT02354547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
Study NCT01917006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
Study NCT01917006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into specified muscle per protocol on Day 1.
Study NCT00847132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Treatment
Description: Depression education, treatment recommendations, coordination of care
Study NCT00847132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Treatment
Description: Treatment as usual, providers are notified of diagnoses
Study NCT03677245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strider Balance Bike
Description: Learning to ride a Strider balance bike
Study NCT01161446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Description: Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
Study NCT01161446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Description: The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
Study NCT03204500 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Active treatment with dual therapy
Description: Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
Study NCT03204500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered orally under the same conditions
Study NCT04178447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Single dose of Glepaglutide 10 mg
Study NCT03277677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: for resuscitation in sepsis patients
Study NCT03277677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Acetate
Description: for resuscitation in sepsis patients
Study NCT01585441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
Study NCT01585441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active ingredients to mimic finasteride
Study NCT01448369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blephasteam
Description: 10 minute treatment twice daily
Study NCT01448369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EyeGiene
Description: 10 minute treatment, twice daily
Study NCT01448369 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hot compresses
Description: 10 minute treatment, twice daily
Study NCT02191527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIMA® for quantitative analysis of CD4-count
Study NCT02191527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin
Study NCT02191527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Given by vein, Days 1, 5, 8, 11
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given by mouth at bedtime, Days 5-8
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by mouth, once per day Days 5-8
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by vein, Days 5-8 continuous infusion
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Given by vein, days 5-8 continuous infusion
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein days 5-8 continuous infusion
Study NCT00871013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given by vein days 5-8 continuous infusion
Study NCT04485494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical Analysis of Blood Biomarkers
Description: Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
Study NCT04497974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Varying the exposure to sweetness via diet manipulation.
Study NCT04497974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Varying the exposure to sweetness via diet manipulation.
Study NCT00901082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation and information session
Description: Relaxation and information session before the medial branch block
Study NCT00337779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate (GA) 40 mg
Description: Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
Study NCT00337779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg
Description: Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
Study NCT02943785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban-based Regimen
Description: 15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
Study NCT02943785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-based Regimen
Description: Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
Study NCT03118479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole Pill
Description: 10 mg of Anastrozole to be taken daily for 3 months.
Study NCT03118479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel 7.5 g to be applied transdermally daily for 3 months.
Study NCT03118479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: One tablet to be taken daily for 3 months
Study NCT00282152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-STN DBS
Description: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
Study NCT00282152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal drug therapy
Description: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
Study NCT00282152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal drug therapy
Description: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
Study NCT01529411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min).
Study NCT01529411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Undefined (standard care)
Description: All the current interventions used by each institution for the study disease.
Study NCT04361968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted placebo condition
Description: Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
Study NCT01004458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
Study NCT01004458 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Waiting list
Description: The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
Study NCT01490307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
Study NCT02998359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
Study NCT02998359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
Study NCT04361968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo condition
Description: Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream.
Study NCT04361968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dog only condition
Description: Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog.
Study NCT04361968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
Study NCT04104594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sniffin Stick Test
Description: The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic.
Study NCT04104594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sniffin Stick Test
Description: The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic.
Study NCT04104594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: numerical evaluation scale for olfaction
Description: numerical rating scale from 0 (no smell) to 10 (perfect smell)
Study NCT04104594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: numerical evaluation scale for nasal obstruction
Description: numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
Study NCT04104594 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nasal outcome test
Description: list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days
Study NCT04104594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal outcome test
Description: list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days
Study NCT04104594 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dosage of 17 cytokines
Description: dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
Study NCT04104594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dosage of 17 cytokines
Description: dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α